Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Dansaert A"'
Publikováno v:
In Néphrologie & Thérapeutique December 2013 9(7):486-493
Publikováno v:
In Néphrologie & Thérapeutique 2011 7(7):549-557
Publikováno v:
Néphrologie & Thérapeutique. 9:486-493
Resume L’anemie est un symptome frequent chez les patients atteints de maladie renale chronique (MRC), debutant un traitement par hemodialyse (HD), corrige par un apport approprie de fer et d’agent stimulant l’erythropoiese (ASE). L’objectif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abe420de31d58aef719566de284e1359
https://doi.org/10.1016/j.nephro.2013.07.364
https://doi.org/10.1016/j.nephro.2013.07.364
Autor:
A. Mikhail, M. Kaplan, I. Macdougall, R. J. Schmidt, A. Rastogi, W. Wang, S. Tong, M. Mayo, N. Oestreicher, B. Schiller, J. M. Green, R. Verma, K. Leu, R. B. Mortensen, P. R. Young, P. Schatz, D. M. Wojchowski, Y. Shimonaka, Y. Sasaki, K. Yorozu, M. N. Sasaki, K. Ikuta, Y. Kohgo, Y. M. Omori, M. Hiramatsu, N. Momoki, Y. Kakio, N. Shibuto, H. Takeuchi, M. Fukumoto, K. Maruyama, Y. Matsuo, Y. Omori, B. M. Robinson, M. Larkina, D. A. Goodkin, Y. Li, F. Locatelli, J. Nolen, W. Kleophas, R. L. Pisoni, S. Sibbel, S. Brunelli, M. Krishnan, M. Horie, E. Hasegawa, K.-i. Minoshima, C. Ambrus, L. Kerkovits, J. Szegedi, A. Benke, E. Toth, L. Nagy, B. Borbas, A. Rozinka, J. Nemeth, G. Varga, I. Kulcsar, L. Gergely, S. Szakony, I. Kiss, K. Danielson, A. R. Qureshi, O. Heimburger, P. Stenvinkel, B. Lindholm, B. Hylander-Rossner, G. Germanis, M. Hansson, S. Beshara, P. Barany, J.-M. Dueymes, A. Kolko, C. Couchoud, C. Combe, A. Covic, D. Goldsmith, P. Zaoui, L. Gesualdo, G. London, F. Dellanna, J. Mann, M. Turner, M. Muenzberg, K. MacDonald, K. Denhaerynck, I. Abraham, M. B. Sanchez, R. C. Casero, R. V. Ortiz, I. G. Carmelo, S. C. Munoz, E. R. Gomez, C. S. Rodriguez, T. Kuji, T. Fujikawa, M. Kakimoto-Shino, K. Shibata, Y. Toya, S. Umemura, N. Topuzovic, I. Mihaljevic, V. Rupcic, G. Sterner, N. Clyne, J. Toblli, F. Di Gennaro, M. Chmielewski, P. Jagodzinski, M. Lichodziejewska-Niemierko, B. Rutkowski, K. Takasawa, C. Takaeda, H. Ueda, M. Higuchi, T. Maeda, N. Tomosugi, T. F. Moghazy, M. Jakic, L. Zibar, G. Romei Longhena, W. Beck, A. Liebchen, U. Teatini, J. B. Rottembourg, A. Guerin, M. Diaconita, A. Dansaert, K. Koike, K. Fukami, K. Shimamatsu, A. Kawaguchi, S. Okuda
Publikováno v:
Nephrology Dialysis Transplantation. 28:i240-i248
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce9698f69cb2f9b66dfcec900ff159cd
https://doi.org/10.1093/ndt/gft119
https://doi.org/10.1093/ndt/gft119
Autor:
Aurélie Dansaert, Jacques Rottembourg
Publikováno v:
Néphrologie & Thérapeutique. 7:549-557
Resume La darbepoetin alfa est un agent stimulant l’erythropoiese dont la demi-vie d’elimination plus longue, permet d’espacer les injections chez les patients hemodialyses. Un protocole d’injection tous les 15 jours est pratique dans l’uni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c86c6cb6d0302d9bc1b8ba40d302a01d
https://doi.org/10.1016/j.nephro.2011.03.011
https://doi.org/10.1016/j.nephro.2011.03.011
Publikováno v:
Dialysis & Transplantation. 39:260-263
A clinical observation of hyperkalemia in a dialyzed patient operated on 3 times following a perforated colic diverticula, led us to discuss the action site of a cation exchange resin. Other therapeutic possibilities to manage hyperkalemia in a non-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a28f9238ac0b74015a89f50f54c48ec
https://doi.org/10.1002/dat.20446
https://doi.org/10.1002/dat.20446
Publikováno v:
Dialysis & Transplantation. 38:493-499
BACKGROUND Darbepoetin alfa (DA) is an erythropoietin-stimulating agent (ESA) preferably administered through intravenous (IV) route in hemodialysis (HD) patients. Although some in vitro studies suggest the possibility of partial adsorption of ESAs i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70b5af88b5a46d22af6a112116880476
https://doi.org/10.1002/dat.20397
https://doi.org/10.1002/dat.20397
Publikováno v:
Journal of Clinical Case Reports. 4
Background: An unacceptably high number of patients start dialysis with pronounced anaemia. The aim of this retrospective study was to provide insights into the impact of the pre-dialysis correction of anaemia (using an ESA) and iron deficiency (usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c34f9a9d4df0e36f9060b53bf5cc2a3
https://doi.org/10.4172/2165-7920.1000462
https://doi.org/10.4172/2165-7920.1000462
Publikováno v:
BMC Nephrology
Background Hemoglobin (Hb) variability is a common occurrence in hemodialysis patients treated with erythropoiesis-stimulating agents. High amplitude fluctuations have been associated with greater risk of morbidity and mortality. Methods This prospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6d02cfbb316f09efbc4faee1573f5b6
https://doi.org/10.1186/1471-2369-14-243
https://doi.org/10.1186/1471-2369-14-243
Publikováno v:
Nephrologietherapeutique. 9(7)
Individualized use of iron therapy (IT) and erythropoiesis-stimulating agents (ESA) may effectively correct anemia and its symptoms in CKD patients (Pts). The aim of this retrospective study was to precise the anemia management (AM) in incident HD Pt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::05d98e12e7c507307181187739424d68
https://pubmed.ncbi.nlm.nih.gov/24113201
https://pubmed.ncbi.nlm.nih.gov/24113201